Abstract
Major and mild neurocognitive disorders are often managed by physicians in multiple specialties including primary practice, psychiatry, geriatric medicine, and neurology. Major and mild neurocognitive disorders are classified according to the known etiological or pathological entities underlying the cognitive impairment. For certain types, the diagnosis depends on the presence of a potentially causative entity, such as Parkinson disease, other parkinsonism, vascular disease, or traumatic brain injury. For other etiologies, such as Alzheimer disease, frontotemporal lobar degeneration, and Lewy body disease, the diagnosis is based primarily on the cognitive, behavioral, and functional symptoms. The differentiation among these multiple types of neurocognitive disorders becomes more evident at the level of major neurocognitive disorder than at the level of mild neurocognitive disorder, but characteristic features can be present at the mild level as well. For many types, international expert groups have developed specialized consensus criteria based on clinicopathological correlation with underlying brain pathology. This section reviews the diagnostic guidelines, clinical presentations, differential diagnosis, and treatment considerations of the four main types: neurocognitive disorder due to Alzheimer disease, frontotemporal neurocognitive disorder, neurocognitive disorder due to Lewy bodies, and vascular neurocognitive disorder.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Roberts RO, Geda YE, Knopman DS, et al. The incidence of MCI differs by subtype and is higher in men: the Mayo Clinic Study of Aging. Neurology. 2012;78(5):342–51.
Ismail Z, Smith EE, Geda Y, et al. Neuropsychiatric symptoms as early manifestations of emergent dementia: provisional diagnostic criteria for mild behavioral impairment. Alzheimers Dement. 2016;12(2):195–202.
Ismail Z, Agüera-Ortiz L, Brodaty H, et al. The mild behavioral impairment checklist (MBI-C): a rating scale for neuropsychiatric symptoms in pre-dementia populations. J Alzheimers Dis. 2017;56(3):929–38.
Woolley JD, Khan BK, Murthy NK, Miller BL, Rankin KP. The diagnostic challenge of psychiatric symptoms in neurodegenerative disease; rates of and risk factors for prior psychiatric diagnosis in patients with early neurodegenerative disease. J Clin Psychiatry. 2011;72(2):126–33.
Taragano FE, Allegri RF, Krupitzki H, et al. Mild behavioral impairment and risk of dementia: a prospective cohort study of 358 patients. J Clin Psychiatry. 2009;70:584–92.
Rosenberg PB, Mielke MM, Appleby BS, Oh ES, Geda YE, Lyketsos CG. The association of neuropsychiatric symptoms in MCI with incident dementia and Alzheimer’s disease. Am J Geriatr Psychiatry. 2013;21(7):685–95. https://doi.org/10.1016/j.jagp.2013.01.006.
Peters M, Rosenberg P, Steinberg M, et al. Neuropsychiatric symptoms as risk factors for progression from CIND to dementia: the Cache County Study. Am J Geriatr Psychiatry. 2013;21(11):1116–24. https://doi.org/10.1016/j.jagp.2013.01.049.
Pink A, Stokin GB, Bartley MM, et al. Neuropsychiatric symptoms, APOE ε4, and the risk of incident dementia: a population-based study. Neurology. 2015;84(9):935–43.
Petersen RC. Early diagnosis of Alzheimer’s disease: is MCI too late? Curr Alzheimer Res. 2009;6(4):324–30.
Köhler S, Thomas AJ, Barnett NA, O’Brien JT. The pattern and course of cognitive impairment in late-life depression. Psychol Med. 2010;40(4):591–602.
Singh-Manoux A, Dugravot A, Fournier A, Abell J, Ebmeier K, Kivimäki M, Sabia S. Trajectories of depressive symptoms before diagnosis of dementia: a 28-year follow-up study. JAMA Psychiatry. 2017;74(7):712–8.
Mirza SS, de Bruijn RF, Direk N, et al. Depressive symptoms predict incident dementia during short- but not long-term follow-up period. Alzheimers Dement. 2014;10(5 Suppl):S323–9.e1.
Almeida OP, Hankey GJ, Yeap BB, Golledge J, Flicker L. Depression as a modifiable factor to decrease the risk of dementia. Transl Psychiatry. 2017;7(5):e1117.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Publishing; 2013.
Clark LR, Stricker NH, Libon DJ, et al. Yes/No versus forced-choice recognition memory in mild cognitive impairment and Alzheimer’s disease: patterns of impairment and associations with dementia severity. Clin Neuropsychol. 2012;26(7):1201–16.
Budson AE, Solomon PR. New diagnostic criteria for Alzheimer’s disease and mild cognitive impairment for the practical neurologist. Pract Neurol. 2012;12:88–96.
Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol. 2014;13(6):614–29.
Molin P, Rockwood K. The new criteria for Alzheimer’s disease—implications for geriatricians. Can Geriatr J. 2016;19(2):66–73.
Hategan A, Xiong GL. Major or mild neurocognitive disorder due to Alzheimer disease. In: Hategan, et al., editors. Geriatric psychiatry: a case-based textbook. Springer; 2018, p. 369–401.
Patterson C, Feightner JW, Garcia A, Hsiung G-YR, MacKnight C, Sadovnick AD. Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease. CMAJ. 2008;178(5):548–56.
Rahayel S, Frasnelli J, Joubert S. The effect of Alzheimer’s disease and Parkinson’s disease on olfaction: a meta-analysis. Behav Brain Res. 2012;231(1):60–74.
Velayudhan L, Pritchard M, Powell JF, Proitsi P, Lovestone S. Smell identification function as a severity and progression marker in Alzheimer’s disease. Int Psychogeriatr. 2013;25(7):1157–66.
Wehling EI, Lundervold AJ, Nordin S, Wollschlaeger D. Longitudinal changes in familiarity, free and cued odor identification, and edibility judgments for odors in aging individuals. Chem Senses. 2016;41(2):155–61.
Lafaille-Magnan ME, Poirier J, Etienne P, et al. PREVENT-AD Research Group. Odor identification as a biomarker of preclinical AD in older adults at risk. Neurology. 2017;89(4):327–35.
Growdon ME, Schultz AP, Dagley AS, et al. Odor identification and Alzheimer disease biomarkers in clinically normal elderly. Neurology. 2015;84(21):2153–60.
Doty RL, Shaman P, Dann M. Development of the University of Pennsylvania Smell Identification Test: a standardized microencapsulated test of olfactory function. Physiol Behav. 1984;32(3):489–502.
Doty RL, Frye RE, Agrawal U. Internal consistency reliability of the fractionated and whole University of Pennsylvania Smell Identification Test. Percept Psychophys. 1989;45(5):381–4.
Da Silva MNM, Millington RS, Bridge H, James-Galton M, Plant GT. Visual dysfunction in posterior cortical atrophy. Front Neurol. 2017;8:389. https://doi.org/10.3389/fneur.2017.00389.
Benson DF, Davis RJ, Snyder BD. Posterior cortical atrophy. Arch Neurol. 1988;45(7):789–93.
Tang-Wai DF, Graff-Radford NR, Boeve BF, et al. Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy. Neurology. 2004;63(7):1168–74.
Caine D. Posterior cortical atrophy: a review of literature. Neurocase. 2004;10(5):382–5.
Schmidt C, Wolff M, Weitz M, Bartlau T, Korth C, Zerr I. Rapidly progressive Alzheimer disease. Arch Neurol. 2011;68(9):1124–30.
Schott JM, Warren JD. Alzheimer’s disease: mimics and chameleons. Pract Neurol. 2012;12(6):358–66.
Blennow K, de Leon MJ, Zetterberg H. Alzheimer’s disease. Lancet. 2006;368(9533):387–403.
Rogan S, Lippa CF. Alzheimer’s disease and other dementias: a review. Am J Alzheimers Dis Other Demen. 2002;17:11–7.
Trzepacz PT, Hochstetler H, Wang S, Walker B, Saykin AJ, Alzheimer’s Disease Neuroimaging Initiative. Relationship between the Montreal Cognitive Assessment and Mini-mental State Examination for assessment of mild cognitive impairment in older adults. BMC Geriatr. 2015;15:107. https://doi.org/10.1186/s12877–015–0103–3.
Hollis AM, Duncanson H, Kapust LR, Xi PM, O’Connor MG. Validity of the mini-mental state examination and the montreal cognitive assessment in the prediction of driving test outcome. J Am Geriatr Soc. 2015;63(5):988–92.
Gauthier S, Patterson C, Chertkow H, et al. Recommendations of the 4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD4). Can Geriatr J. 2012;15(4):120–6.
Lee L, Molnar F. Driving and dementia: efficient approach to driving safety concerns in family practice. Can Fam Physician. 2017;63(1):27–31.
Roy M, Molnar F. Systematic review of the evidence for Trails B cut-off scores in assessing fitness-to-drive. Can Geriatr J. 2013;16(3):120–42.
Papandonatos GD, Ott BR, Davis JD, Barco PP, Carr DB. The clinical utility of the trail making tests as predictors of driving performance in older adults. J Am Geriatr Soc. 2015;63(11):2358–64.
Marshall GA, Amariglio RE, Sperling RA, Rentz DM. Activities of daily living: where do they fit in the diagnosis of Alzheimer’s disease? Neurodegener Dis Manag. 2012;2(5):483–91.
Livingston G, Sommerlad A, Orgeta V, et al. Dementia prevention, intervention, and care. Lancet. 2017;390(10113):2673–734. https://doi.org/10.1016/S0140-6736(17)31363-6. pii: S0140-6736(17)31363-6.
Hsiung GY, Sadovnick AD. Genetics and dementia: risk factors, diagnosis, and management. Alzheimers Dement. 2007;3(4):418–27.
Campion D, Dumanchin C, Hannequin D, et al. Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am J Hum Genet. 1999;65(3):664–70.
Sleegers K, Roks G, Theuns J, et al. Familial clustering and genetic risk for dementia in a genetically isolated Dutch population. Brain. 2004;127(Pt 7):1641–9.
Rademakers R, Cruts M, Van Broeckhoven C. Genetics of early-onset Alzheimer dementia. Sci World J. 2003;3:497–519.
Cupples LA, Farrer LA, Sadovnick AD, Relkin N, Whitehouse P, Green RC. Estimating risk curves for first-degree relatives of patients with Alzheimer’s disease: the REVEAL study. Genet Med. 2004;6(4):192–6.
Patterson C, Feightner J, Garcia A, MacKnight C. General risk factors for dementia: a systematic evidence review. Alzheimers Dement. 2007;3(4):341–7.
National Academies of Sciences, Engineering, and Medicine. Preventing cognitive decline and dementia: a way forward. Washington, DC: The National Academies Press; 2017. https://doi.org/10.17226/24782. Accessed 3 Nov 2017.
Alexopoulos GS, Meyers BS, Young RC, Campbell S, Silbersweig D, Charlson M. ‘Vascular depression’ hypothesis. Arch Gen Psychiatry. 1997;54(10):915–22.
Aizenstein HJ, Baskys A, Boldrini M, et al. Vascular depression consensus report—a critical update. BMC Med. 2016;14(1):161.
Diniz BS, Butters MA, Albert SM, Dew MA, Reynolds CF 3rd. Late-life depression and risk of vascular dementia and Alzheimer’s disease: systematic review and meta-analysis of community-based cohort studies. Br J Psychiatry. 2013;202(5):329–35.
Gorelick PB, Scuteri A, Black SE, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(9):2672–713.
Burhan AM, Moradizadeh M, Marlatt N. Major or mild vascular neurocognitive disorder. In: Hategan, et al., editors. Geriatric psychiatry: a case-based textbook. Springer; 2018, p. 445–66.
Olney NT, Spina S, Miller BL. Frontotemporal dementia. Neurol Clin. 2017;35(2):339–74.
Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a frontal assessment battery at bedside. Neurology. 2000;55(11):1621–6.
Milan G, Lamenza F, Iavarone A, et al. Frontal Behavioural Inventory in the differential diagnosis of dementia. Acta Neurol Scand. 2008;117(4):260–5.
De Deyn PP, Engelborghs S, Saerens J, et al. The Middelheim Frontality Score: a behavioural assessment scale that discriminates frontotemporal dementia from Alzheimer’s disease. Int J Geriatr Psychiatry. 2005;20:70–9.
Bora E, Velakoulis D, Walterfang M. Meta-analysis of facial emotion recognition in behavioral variant frontotemporal dementia: comparison with Alzheimer disease and healthy controls. J Geriatr Psychiatry Neurol. 2016;29(4):205–11.
Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–9.
McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996;47:1113–24.
McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies third report of the DLB consortium. Neurology. 2005;65(12):1863–72.
Kales HC, Gitlin LN, Lyketsos CG. Assessment and management of behavioral and psychological symptoms of dementia. BMJ. 2015;350:h369.
Massoud F, Leger G. Pharmacological treatment of Alzheimer disease. Can J Psychiatry. 2011;56(10):579–88.
Reisberg B, Ferris SH, de Leon MJ, Crook T. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry. 1982;139(9):1136–9.
Yorkshire and the Humber Clinical Networks. The assessment of cardiac status before prescribing acetyl cholinesterase inhibitors for dementia. First published April 2016. Reviewed October 2017. http://www.yhscn.nhs.uk/media/PDFs/mhdn/Dementia/ECG%20Documents/ACHEIGuidance%20V1_Final.pdf. Accessed 8 Oct 2017.
Rowland JP, Rigby J, Harper AC, Rowland R. Cardiovascular monitoring with acetylcholinesterase inhibitors: a clinical protocol. Adv Psychiatr Treat. 2007;13(3):178–84.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Hategan, A., Bourgeois, J.A., Cheng, T., Young, J. (2018). Common Major and Mild Neurocognitive Disorders: Alzheimer Disease, Frontotemporal, Lewy Body, and Vascular Types. In: Geriatric Psychiatry Study Guide. Springer, Cham. https://doi.org/10.1007/978-3-319-77128-1_9
Download citation
DOI: https://doi.org/10.1007/978-3-319-77128-1_9
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-77127-4
Online ISBN: 978-3-319-77128-1
eBook Packages: MedicineMedicine (R0)